MRI and Recurrence Rates in Women With DCIS

Video

Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, gives an overview of the background and results from a study that analyzed perioperative MRI and recurrence rates in women with DCIS.

Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, gives an overview of the background and results from a study that analyzed perioperative MRI and recurrence rates in women with DCIS.

This large retrospective study was done to evaluate the association of MRI and long-term outcomes, meaning locoregional recurrence and contralateral breast cancer in women with DCIS. Researchers found that there was no difference between the rates of locoregional recurrence and those women with or without a perioperative MRI at 5 and 8 years. There was also no significant difference observed in the rates of locoregional recurrence at 5 or 8 years in women who did not have radiation therapy, though theoretically these patients would benefit most from the addition of MRI. There was also no difference in the rates of contralateral breast cancer between women with and without MRI.

Clinical Pearls

Ultimately, Pilewskie says, these data add to the literature that MRI use for women with DCIS is not associated with improved outcomes.

  • This study was done to evaluate the association of perioperative MRI and long-term outcomes
  • There was no association observed between perioperative MRI and locoregional recurrence rates for patients with DCIS, even when radiotherapy was not given
Related Videos
Video 7 - "Unmet Needs and Future Directions in HER2+ Breast Cancer"
Video 6 - "Current Approaches to Treatment Sequencing in HER2+ Breast Cancer"
Video 5 - "Exciting Developments in HER2+ Breast Cancer"
Video 4 - "KATHERINE: Adjuvant T-DM1 vs Trastuzumab for Residual Invasive HER2+ Breast Cancer"
Video 3 - "APHINITY Trial: Pertuzumab for Patients with HER2+ Breast Cancer"
Related Content